News & Updates

For small-sized melanoma in situ (MIS; <10 mm) on low-risk body sites, wide local excision (WLE) using a 5-mm margin was associated with a low rate of recurrence, a retrospective case series study has shown.

In older patients with untreated mantle cell lymphoma (MCL), the addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab (ABR) conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a favourable trend for overall survival (OS), findings from the phase III ECHO trial have shown.

A strong, positive link between BMI and the risk of colorectal cancer (CRC) incidence and related deaths has been found in Asian populations.

In the phase III ASC4FIRST study, asciminib – the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP) – trumped all investigator-selected tyrosine kinase inhibitors (IS-TKIs; imatinib, nilotinib, dasatinib, and bosutinib) for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).

Patients with a diagnosis of lymphangioleiomyomatosis (LAM) are at higher risk of developing lung cancer, reveals a recent study.